CURE’s breast cancer page is an extensive resource of cancer information featuring the latest breast cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on breast cancer.
June 19th 2025
Speaking up during cancer treatment helped one patient manage side effects, address insurance issues and stay productive throughout chemotherapy.
Debu Tripathy Discusses a Clinical Trial of Ibrance in Breast Cancer
June 11th 2015Debu Tripathy, editor-in-chief of CURE and chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses adding the targeted drug Ibrance to the hormonal drug Faslodex.
Adding Ibrance to Faslodex Delays Progression of Hormone Receptor-Positive Breast Cancer
June 1st 2015By adding the targeted drug Ibrance to the hormonal drug Faslodex, women with previously treated hormone receptor (HR)-positive, HER2-negative breast cancer delayed disease progression by more than five months.